Articles

Traditional myeloablative conditioning remains the standard of care for preparing patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) for transplant, according to a randomized trial from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN). The study, presented as a late-breaker at ASH 2015, was halted after a reduced-­intensity conditioning (RIC) regimen proved less effective.

In patients with B-cell precursor acute lymphoblastic leukemia (BCP-ALL), the addition of rituximab (Rituxan) to chemotherapy significantly improved event-free survival in a large European study.

Monoclonal antibodies targeting PD-1 may be effective in multiple myeloma, according to early data from 2 clinical trials on pembrolizumab (Keytruda) presented at ASH 2015.

As one part of an ongoing macrotheme regarding big data, understanding the benefits and limitations of using drug claims in employer-based population health is an important topic for employers in their health plan coverage strategies. Pharmacy claims are a common source of data used to describe the uses of cancer medications by employees and by their covered family members. Despite the availability of these data and a plethora of analyses, however, several limitations must be considered when interpreting drug use data.

Oral targeted therapies, such as ibrutinib (Imbruvica) and idelalisib (Zydelig), represent a major advance for patients with chronic lymphocytic leukemia (CLL) and have undoubtedly changed the treatment paradigm for this disease and the clinical outcomes.

Chimeric antigen receptor (CAR) T-cell therapy has been striking in various hematologic malignancies, and for the first time this treatment approach is being evaluated in multiple myeloma.

Elderly patients with Philadelphia-negative B-cell acute lymphoblastic leukemia (ALL) have overall poor outcomes with current therapies. Results of a new study presented at ASH 2015 suggest that frontline treatment with the investigational antibody-drug conjugate inotuzumab ozogamicin in combination with deintensified chemotherapy is a good option for older patients with this disease.

A panel of 4 blood-derived biomarkers showed promise as an aid to early detection of colo­rectal cancer (CRC). The panel yielded a negative predictive value exceeding 90% for CRC, the combination of CRC and high-risk adenomas, and colorectal plus other cancers. The biomarker assay demonstrated fair to good performance characteristics, associated with the receiver operating characteristic (ROC) curve ranging between 0.70 and 0.80.

A liquid biopsy using phlebotomy blood samples can identify phenotypes and genomic characteristics of circulating tumor cells that may personalize treatment selection for men with advanced prostate cancer, according to the results of a study presented by Howard I. Scher, MD, Chief, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, NY, at the 2016 ASCO Genitourinary Cancers Symposium.